ClinicalTrials.gg
RecruitingNCT06400537Updated Sep 17, 2025

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus

A Phase 1 interventional study of A-319 in Systemic Lupus Erythematosus, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 2 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — 8 open to participants now, 8 under way, none of them phase 3. Lupus Erythematosus, Systemic · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Planned enrollment
2nd of 11
25 · median 12
Started
2024
with 2 others
Phase 1
7 of 11
5 open now
Registered
3rd of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2024, is one of 7 in phase 1, and was the 3rd registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

8 of the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, or all of them as a file.
02

Study summary

The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).

Read the detailed description

The pathogenic B cells of patients with SLE can produce a large amount of autoantibodies, which will form immune complexes and thereby inducing continuously expanding tissue damage and systemic inflammation. A-319 is a kind of recombinant CD19xCD3 double antibody, it can activate internal T cells to target and kill pathogenic B cells. Clinical trials of A-319 are currently underway in hematological maliganancies concerning B cell abnormality. Preclinical studies have shown the efficacy of A-319 in SLE. The aim of this study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and preliminary efficacy of A-319 in active/refractory SLE. Patients with active/refractory SLE will be invited to participate in the study, to receive A-319 intravenous infusion or subcutaneous injection and follow-up visits of up to 1 years after enrollment.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • systemic lupus erythematosus
  • A-319
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-60 years old, regardless of gender;
  2. Participants diagnosed with SLE according to the American College of Rheumatology (ACR) 1997 revised criteria for SLE at least 24 weeks prior to signing the form;
  3. Active/ systemic lupus erythematosus;
  4. Positive test results for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) immunofluorescence assay at a titer of ≥1:80; anti-dsDNA; or anti-Smith (anti-Sm);
  5. Receive the standardized and stable treatment for at least 30 days before the first administration of the study drug;
  6. Female participants tested negative for pregnancy, and participants agreed to use effective throughout the trial;
  7. Have the ability to understand the nature of the research and voluntarily sign an informed consent form;
  8. Participants can communicate well with the researchers and complete all visits according to the requirements of the plan.

Exclusion criteria

Exclusion Criteria:

  1. Severe kidney disease;
  2. Participants who have central nervous system diseases caused by SLE or non-SLE disease within 8 weeks before the first administration of the study drug;
  3. Abnormities of main organ function at screening;
  4. Medical history that the researchers believe will pose risk to the safety of the participants, or will affect the safety or effectiveness analysis of the study drug;
  5. Active mycobacterium tuberculosis infection;
  6. Active hepatitis, or virus surface antigen positive, or hepatitis B virus core antibody positive and hepatitis B virus deoxyribonucleic acid positive, ,or virus (HCV) antibody positive with detectable HCV ribonucleic acid (RNA).;
  7. History of infection, or positive antibodies at screening;
  8. Positive syphilis spirochete antibody at screening (except false positive caused by SLE);
  9. Participants with chronic active infection or acute infection need systemic anti-infection treatment within 2 weeks before screening, or have superficial skin infection requiring treatment within 1 week before screening;
  10. Have undergone major surgery or unhealed wounds, ulcers or fractures within 4 weeks before the first administration of the study drug, or plan to perform major surgery during the study period;
  11. Participants diagonosed with malignant tumors within 5 years before screening;
  12. History of important organ transplantation or hematopoietic stem cells/or bone marrow transplantation;
  13. Have been vaccinated or plan to receive or live attenuated vaccine during the research period within 4 weeks before the first administration of the study drug;
  14. Participated in any clinical trial within 4 weeks before the first administration of the study drug or within 5 half-lives of the study drug of the clinical trial;
  15. Received targeted drugs (rituximab, JAK inhibitors, etc.) at a specific time period before the first administration of the study drug;
  16. Received intravenous immunoglobulin, prednisone ≥100mg/d or equivalent therapy within 4 weeks before the first administration of the study drug, or plasma replacement;
  17. Received IL-2, thalidomide, rethidone and traditional Chinese medicine within 4 weeks before the first administration of the study drug;
  18. Known allergies to monoclonal antibody drugs, or allergies to A-319 ;
  19. Participants with depression or suicidal thoughts;
  20. Women who are pregnant or breastfeeding, or women who plan to be pregnant or breastfeeding during the study period; or men whose sexual partners plan to become pregnant during the study period;
  21. Any reason that the researchers believe will hinder the subject's participation in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    A-319 intravenous intervention

    A-319 will be preset with 3 escalation dose levels by intravenous infusion: dose A, dose B, dose C, total course of treatment: 4 weeks. Anticipated enrollment: 9-18 participants.

    Biological: A-319

  • Experimental
    A-319 subcutaneous intervention

    A-319 will be administered via subcutaneous injection at five preset escalating dose levels: Dose A, Dose B, Dose C, Dose D, and Dose E. The total treatment duration is 4 weeks. Each dose group is planned to enroll 3+N (N=0-12) participants, with a total anticipated enrollment of 16-32 study participants.

    Biological: A-319

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Safety and tolerability will be assessed by incidence and severity of adverse events (AEs) and serious AEs (SAEs)

    Time frame: Within 1 year since A-319 infusion

Secondary outcomes

  1. Pharmacokinetics of A-319

    Concentration of A-319 in peripheral blood will be evaluated

    Time frame: Within 1 month since A-319 infusion

  2. Pharmacodynamics of A-319

    Pharmacodynamics will be assessed by levels of cytokines (IL-6, IL-8, IL-10, IFN-γ, TNF-α) in peripheral blood

    Time frame: Within 1 month since A-319 infusion

  3. Pharmacodynamics of A-319

    Pharmacodynamics will be assessed by levels of lymphocyte subsets in peripheral blood

    Time frame: Within 1 month since A-319 infusion

  4. Numbers of Participants with positive antidrug antibodies in peripheral blood

    To evaluate immunogenicity of A-319

    Time frame: Day 28 and month 3 since A-319 infusion

Other outcomes

  1. Changes in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2000) from baseline

    Range \[0, 105\],higher score represents worse disease activity

    Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)

  2. Changes in the Physician Global Assessment (PGA) score from baseline

    Range \[0, 3\],higher score represents worse disease activity

    Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)

  3. Changes in the BILAG-2004 score from baseline

    Range \[0, 72\],higher score represents worse disease activity

    Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)

  4. Changes in immunological indexes from baseline

    Serum IgA, IgG, IgE and IgM will be evaluated

    Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)

  5. Changes in level of anti-nuclear antibody (ANA) in peripheral blood from baseline

    To evaluate SLE disease activity

    Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)

  6. Changes in level of anti-double stranded DNA (dsDNA) antibody in peripheral blood from baseline

    To evaluate SLE disease activity

    Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)

  7. Changes in levels of complement C3 in peripheral blood from baseline

    To evaluate SLE disease activity

    Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)

  8. Changes in levels of complement C4 in peripheral blood from baseline

    To evaluate SLE disease activity

    Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)

  9. The therapeutic effect of A-319 on impaired organs in active/refractory SLE patients

    Pathological samples of impaired organs will be analyzed

    Time frame: Within 1 year since A-319 infusion

  10. The clearance effect of A319 on CD19+B cells in active/refractory SLE patients

    To evaluate SLE disease activity

    Time frame: Within 28 days since A-319 infusion

  11. The effect of A-319 on gene expression in peripheral blood lymphocytes of active/refractory SLE

    To investigate the mechanism of action of A-319 in SLE

    Time frame: Day 28 and month 3 since A-319 infusion

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 147 phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2024
First posted
May 6, 2024
StartActual
Jul 20, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06400537
Collaborators
ITabMed Co., Ltd.
Responsible party
Qiubai Li (Director, Head of Department of Rheumatology and Immunology, Principal Investigator, Professor, Wuhan Union Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
May 6, 2024
Start date
Jul 20, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Qiubai Li, Professor
Contact
qiubaili@hust.edu.cn
85726808 ext. 027
Di Wu
Contact
373181302@qq.com
18790696175 ext. 86
Qiubai Li, Professor
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CD3-activating CD19 Bi-specific Antibody A-319

Start the discussion